Passage Bio, Inc. Common Stock (PASG)
Passage Bio, Inc. is a biopharmaceutical company focused on developing gene therapies for rare and devastating neurological and genetic disorders. Established with the goal of transforming patient lives, Passage Bio leverages its proprietary platform to discover and develop treatments targeting novel genetic and neurological conditions.
Company News
The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.
The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Shares of BlackBerry Limited (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results. BlackBerry reported quarterly earnings of 1 cent per share which exceeded the Street's estimate of losses of 3 cents per share, according to Benzinga Pro. The company also said it sees fourth-quarter revenue of $150 million ...